The cardiac IKs ion channel comprises KCNQ1, calmodulin, and KCNE1 in a dodecameric complex which provides a repolarizing current reserve at higher heart rates and protects from arrhythmia syndromes that cause fainting and sudden death. Pharmacological activators of IKs are therefore of interest both scientifically and therapeutically for treatment of IKs loss-of-function disorders. One group of chemical activators are only active in the presence of the accessory KCNE1 subunit and here we investigate this phenomenon using molecular modeling techniques and mutagenesis scanning in mammalian cells. A generalized activator binding pocket is formed extracellularly by KCNE1, the domain-swapped S1 helices of one KCNQ1 subunit and the pore/turret region made up of two other KCNQ1 subunits. A few residues, including K41, A44 and Y46 in KCNE1, W323 in the KCNQ1 pore, and Y148 in the KCNQ1 S1 domain, appear critical for the binding of structurally diverse molecules, but in addition, molecular modeling studies suggest that induced fit by structurally different molecules underlies the generalized nature of the binding pocket. Activation of IKs is enhanced by stabilization of the KCNQ1-S1/KCNE1/pore complex, which ultimately slows deactivation of the current, and promotes outward current summation at higher pulse rates. Our results provide a mechanistic explanation of enhanced IKs currents by these activator compounds and provide a map for future design of more potent therapeutically useful molecules.
Combined, KCNQ1 and KCNE1 subunits generate the IKs current. Activating IKs has been identified as a promising therapeutic strategy to treat arrhythmogenesis resulting from delayed repolarization. In this study, we uncovered a common drug-induced binding site accessed by two structurally diverse IKs activators, mefenamic acid and DIDS. Located in the extracellular interface where KCNE1 interacts with KCNQ1, we propose that binding of drugs to this location impairs channel closing and leads to enhanced current activation. This is shown to be particularly beneficial at higher pulse rates and explains how such drugs may make an important contribution to the electrical repolarization reserve in the heart.
By combining electrophysiological analysis of mutant channels and molecular dynamics simulations, this important study identifies a common binding site for two structurally distinct activators of KCNQ1-KCNE1 channels. The findings represent an important advance for the field, with convincing functional data to support it. The simulations are still partially incomplete and would benefit from additional data and discussion. The work will be of interest to those studying the binding of small molecule drugs to membrane protein complexes.
Potassium ion (K+) channel activators are important compounds in human health, as partial or complete loss of function of many K+ channels may lead to inherited or acquired diseases that have significant morbidity and mortality. The delayed cardiac rectifier potassium current, IKs, plays an important role, especially at high heart rates, in the physiological shortening of the cardiac action potential (Sanguinetti et al., 1996). Unsurprisingly, mutations in both KCNQ1 (α-subunit) and KCNE1 (β-subunit), which when paired together give rise to the IKs current (Barhanin et al., 1996Sanguinetti et al., 1996Bendahhou et al., 2005), have been implicated in cardiac arrhythmia syndromes such as long QT syndrome (LQTS) and atrial fibrillation (Jervell and Lange-Nielsen, 1957Wang et al., 1996Chen et al., 2003Eldstrom and Fedida, 2011Olesen et al., 2014). With nearly all mutations seen in LQTS patients identified as loss-of-function and 50% of those loss-of-function mutations identified in the KCNQ1 subunit (Hedley et al., 2009Ackerman et al., 2011), enhancing and activating IKs currents has long been suggested as a promising therapeutic approach for treating LQTS. It is a curiosity of IKs channels that the known activators fall into two general groupings: those that work best on the α-subunit, KCNQ1, alone, including zinc pyrithione, L-364,373, and one of the most studied activators, ML277 (Mattmann et al., 2012Yu et al., 2013Xu et al., 2015Eldstrom et al., 2021); and those that work best in the presence of the auxiliary β-subunit, KCNE1, compounds like mefenamic acid and DIDS (4,4’-diisothiocyano-2,2’-stilbene disulfonic acid) (Abitbol et al., 1999Wang et al., 2020).
Using cryo-EM, we recently visualized the binding of ML277 deep in the central core of KCNQ1 channels in a pocket lined inferiorly by the S4-S5 linker, laterally by the S5 and S6 helices of two separate subunits, and above by pore domain residues (Willegems et al., 2022). The location of the binding pocket and its structural inter-relationships help to explain the underlying mechanism of action of ML277, its specificity for KCNQ1, and the lack of efficacy due to steric hindrance in the presence of a β-subunit. However, it is known neither where activators of IKs bind that require the presence of the β-subunit, such as phenylboronic acid (Mruk and Kobertz, 2009), hexachlorophene, stilbenes such as DIDS and SITS (4-acetamido-4’-isothiocyanatostilbene-2,2’-disulfonic acid), and diclofenac acid derivatives such as mefenamic acid (Abitbol et al., 1999Zheng et al., 2012Wang et al., 2020), nor how they mediate their activator action. We have some clues for DIDS and mefenamic acid that their binding sites are not in the central channel core, as is the case for ML277, but depend on KCNE1 β-subunit residues at the extracellular surface of the channel, residues 39-43 in KCNE1 for DIDS (Abitbol et al., 1999) and K41 for mefenamic acid (Wang et al., 2020). Our recent cysteine scanning data revealed that although other extracellular KCNE1 residues in the same region to varying degrees impacted the effect of mefenamic acid, only the K41C mutation completely abolished mefenamic acid effect up to a concentration of 1 mM (Wang et al., 2020). Previous cross-linking studies have identified key interactions between this extracellular region of KCNE1 and the S1 and S6 transmembrane segments of KCNQ1 (Xu et al., 2008Chung et al., 2009), suggesting that residues in either of these regions could also provide important clues to explain mefenamic acid’s mechanism of action.
To further explore the dependence of residues in KCNE1 and those in adjacent KCNQ1 sites on binding of mefenamic acid to IKs, we first examined the role of K41C in preventing the drug effect. Docking in combination with molecular dynamics (MD) simulations of mefenamic acid binding to IKs followed by mutagenesis were used to map out critical KCNE1 and KCNQ1 residues. Further, we expanded on the idea that the stilbene, DIDS (Abitbol et al., 1999), which is structurally quite different from mefenamic acid, shares a common binding site. Our results showed that both compounds bind in the same general region formed by elements of the pore and S6 domains of KCNQ1 and the near extracellular region of KCNE1, but depend on different critical residues for their binding stability. Exposure of the channel complex to either compound induces subtle structural changes that subsequently stabilize the conformation of the S1/outer pore/S6 of KCNQ1 and slow the IKs deactivation gating kinetics. The results suggest the existence of a common drug-induced binding site and a mechanism of action for small molecule IKs activators which is distinct from that of specific compounds that activate KCNQ1 alone.
The mefenamic acid binding site on the KCNQ1/KCNE1 complex
Exposure of wild type IKs complexes (4:4 ratio; WT EQ) to 100 µM mefenamic acid transforms the slowly activating IKs current into one with an almost linear waveform and completely inhibits tail current decay at -40 mV (Figure 1A) (Abitbol et al., 1999Unsöld et al., 2000Wang et al., 2020). G-V relations obtained from peak initial tail currents show that 100 µM mefenamic acid hyperpolarizes the G-V (ΔV1/2 = -105.7 mV, Figure 1B, 1C) and decreases the slope (control k = 19.4 mV, Mef k = 41.3 mV, Table 1). We previously showed that introduction of a cysteine mutation at residue K41 in all four KCNE1 subunits (4:4 ratio of mutant K41C-KCNE1 to KCNQ1; K41C-EQ) itself had only a minor effect on the G-V, but prevented changes to currents and the G-V relationship on exposure to 100 µM or 1 mM mefenamic acid (Figure 1B, 1C and Table 1) (Wang et al., 2020). The data suggest that residue K41 in KCNE1 is critical to the action of mefenamic acid, but give no information why K41 is so important, and prompted us to question how this residue and other adjacent residues in KCNE1, and those nearby on KCNQ1 acted together to form a binding pocket for mefenamic acid.
Mefenamic acid binding site predicted by molecular modeling
Initially, to visualise potential drug binding sites and understand how mutation of KCNE1 and KCNQ1 residues might prevent drug action, in silico experiments of drug docking with subsequent MD simulations were performed on a model of IKs channels. The IKs model was constructed based on the recent cryo-EM structure of KCNQ1-KCNE3, which is thought to represent the activated-open state of the channel complex (Sun and MacKinnon, 2020). Taking into consideration the sequence similarity of KCNE1 and KCNE3 subunits in their transmembrane segments, it has been suggested that the main interface of these subunits with KCNQ1 is preserved in this region. Our initial data indicated that the extracellular residues of KCNE1 are involved in the action of IKs activators, so we constructed a model where external KCNE3 residues R53-Y58 were substituted with homologous KCNE1 residues, D39-A44 (Figure 2A). The resulting 4:4 IKs channel complex was termed pseudo-KCNE1-KCNQ1, ps-IKs, and Figure 2B shows the essential elements of the ps-IKs subunits which form extracellular interface of KCNQ1 and KCNE and served as a basis for drug docking and MD simulations. Details of the docking procedure are described in the Methods section and schematically summarized in Figure 2-figure supplement 1.
Briefly, conformational sampling was performed on ps-IKs residues D39-A44, and conformations showing the lowest free energy were selected for docking using a four-dimensional (4D) docking approach to find the best binding pose of the ligand. A conformation with the best docking score (Figure 2B) shows mefenamic acid binding to the pocket formed between extracellular KCNE1 residues, the external S6 transmembrane helix of one subunit, and the S1 transmembrane domain of the neighboring subunit and the pore turret of a third subunit. The estimated volume of the pocket in the mefenamic acid bound state is ~307 Å3 with a hydrophobicity value of ~0.65 kcal/mol (Figure 2C). The free energy of the mefenamic acid-ps-IKs interaction estimated by the MM/GBSA method from 300 ns MD simulations was -39.4 ± 0.3 kcal/mol (Figure 4A), while a similar value of -31.8 ± 1.46 kcal/mol was calculated using the Poisson-Boltzmann surface area (MM/PBSA) model. Mefenamic acid in this complex was stabilized by its hydrophobic and van der Waals contacts with KCNQ1 and KCNE1 subunits as well as by two hydrogen bonds formed between the drug and ps-KCNE1 residues Y46 and E43 (Figure 2D, Supplemental movie S1).
The energy decomposition per amino acid using MM/GBSA and MM/PBSA methods revealed several residues in KCNQ1 and psKCNE1 with significant contributions to mefenamic acid coordination (Figure 2D, Figure 2-figure supplement 2). As expected, these are the KCNE1 residues located at the external region of the auxiliary subunit – amino acids K41 to Y46. In addition, residues W323 and V324 located on the S6 helix as well as residues L142, Q147 and Y148 located on the S1 helix exhibited the lowest interaction free energy scores. We focused on functional validation of the KCNE1 residues K41, L42, E43, A44 and Y46, and KCNQ1 residues W323, V324, L142, Q147 and Y148 by mutation to cysteine, alanine and/or tryptophan, and examining the sensitivity of fully saturated EQ channel complexes to 100 µM mefenamic acid.
Mutational impact on EQ current changes induced by mefenamic acid
The effect of mutations on the current waveform and tail current response to 100 µM mefenamic acid treatment was examined on IKs channels identified as: x-EQ-y where “x” denotes a KCNE1 mutation and “y” denotes a KCNQ1 mutation. In the absence of mefenamic acid (control), most mutations, with the exception of EQ-L142C (Figure 3-figure supplement 1), produced slowly activating currents with rapid tail current decay (Figure 3A).
In the presence of 100 µM mefenamic acid, the waveforms of WT EQ, S6 and pore mutations EQ-V324A, EQ-V324W, EQ-Q147C and EQ-Y148C were all transformed into ones with instantaneous current onset and slowed tail current decay (Figure 3A). Only the EQ-W323A waveform and tail current was largely unaffected by 100 µM mefenamic acid (like K41C-EQ, Figure 1). The EQ-W323C and A44C-EQ current waveforms were also unchanged by 100 µM mefenamic acid, but their tail current decay was slowed. We interpreted this to mean that mefenamic acid binds to EQ-W323C and A44C-EQ mutant open channels and slows closing, but that the drug-channel complex is less stable and mefenamic acid unbinds during the interpulse interval, which relieves drug action between pulses. The summary of the normalized response of the different mutants to mefenamic acid is shown in Figure 3D. G-V plots were obtained from the tail current amplitudes in the absence and presence of 100 µM mefenamic acid, and unlike WT EQ (Figure 1), minimal change in the shape and position of the EQ-W323A G-V plot was seen after exposure to 100 µM mefenamic acid (V1/2 shift of -14.1 mV compared with -105.7 mV seen in WT EQ (Figure 1, Figure 3B, 3E, and Table 1). For the W323C mutation, a less drastic decrease in size compared to alanine, the V1/2 shift seen with 100 µM mefenamic acid increased (EQ-W323C ΔV1/2 = -26.5 mV), suggesting that the size of the W323 residue is important (Figure 3E and Table 1). However, when the neighboring V324 KCNQ1 residue was mutated to a smaller (alanine) or bulkier (tryptophan) residue they both showed the same response to mefenamic acid. Both the V324W and V324A mutations reduced V1/2 shifts caused by 100 µM mefenamic acid to between -14 to -19 mV (Figure 3E and Table 1).
Extracellular S1 residues identified in the MD simulations also proved to be important for mefenamic acid binding, although less so than W323 and K41 residues found in the KCNQ1 extracellular regions of the S6 segment and KCNE1, respectively. Compared to WT, EQ-Y148C reduced the V1/2 shift after exposure to 100 µM mefenamic acid (EQ-Y148C ΔV1/2 = -19.3 mV) and lessened the slope of the G-V relationship (Figure 3C). The Q147C mutant on the other hand, only partially prevented the V1/2 shift observed after mefenamic acid treatment (EQ-Q147C ΔV1/2 = -37.6 mV, Figure 3E).
Other KCNE1 residues located at the N-terminal limit of the KCNE1 transmembrane segment (L42, E43, A44, Y46) were also investigated. Unlike with K41C, but similarly to WT EQ, tail current decay was inhibited in the presence of 100 µM mefenamic acid in all of these mutants, reflected by the normalized response (Figure 3D). In addition, a reduced but statistically significant shift in V1/2 was observed with 100 µM mefenamic acid compared to control in all mutants tested except K41C. (K41C ΔV1/2 = -3.8 mV; L42C ΔV1/2 = -37.1 mV; E43C ΔV1/2 = -24.4 mV; A44C ΔV1/2 = -9.7 mV; Figure 3D). Consistent with previous literature (Gofman et al., 2012Wang et al., 2012Kuenze et al., 2020), Y46C-EQ in control conditions produced a current with faster activation and a complex GV curve which made analysis and an assignment of slope and V1/2 difficult, though a small left shift in the GV curve was visible (data not shown). In lieu of Y46C, G-V data from the Y46A-EQ mutant showed a potent effect of mefenamic acid, equivalent to that of WT with a ΔV1/2 = -106.2 mV (Figure 7-figure supplement 1). These results suggest that mutation of residues further away from the N-terminus of KCNE1 than K41 has diminishing effects on the activator action of mefenamic acid.
Augmented activation of EQ-L142C in the absence of mefenamic acid
Unlike other mutations, the control EQ-L142C current waveform displayed an almost instantaneous current onset, and tail currents showed no decay with our standard protocol (Figure 3-figure supplement 1A). As the control EQ-L142C current waveform qualitatively resembled WT EQ currents in the presence of 100 µM mefenamic acid, G-V plots at different interpulse intervals were compared. At the standard interval of 15 s, the EQ-L142C G-V plot (blue) closely overlapped that of WT EQ in the presence of Mef (solid grey), and at a 30 s interpulse interval, the position of the WT EQ + Mef (grey open circles) and EQ-L142C plots (green) both depolarized significantly (Figure 3-figure supplement 1B). It appeared that the L142C mutation augmented channel activation as much as 100 µM mefenamic acid on WT channels.
In addition, mefenamic acid made the EQ-L142C G-V plot voltage independent, overlapping with the G-V obtained for EQ-L142C with a 7s interpulse interval (pink and red respectively, Figure 3-figure supplement 1B). The data indicate that EQ-L142C is still responsive to mefenamic acid but does so from a heightened state of activation (Table 2).
MD simulations of mutant ps-IKs channels exposed to mefenamic acid
To explore the role played by critical residues, in silico homologous mutations K41C and W323A were introduced into the mefenamic acid-bound ps-IKs channel (Mef-ps-IKs) and the stability of the Mef-mutant complexes was assessed during 300 ns MD simulations compared to the WT-Mef complex. Remarkably, mefenamic acid detached from mutant K41C and W323A channels within 120-140 ns of MD simulations in all three independent runs (Supplemental movies S1-S3) performed for each mutant. In contrast, mefenamic acid remained bound during the entire simulation time to WT and Y46C-ps-IKs complexes (Supplemental movie S4). The last mutant was tested as we could not determine the functional effect of mefenamic acid on this residue in electrophysiological experiments. Mefenamic acid unbound from A44C-ps-IKs channel complexes within 80, 100 and 110 ns during three different simulations, changing binding pose several times before doing so.
A significantly reduced free interaction energy (ΔG) of ligand binding for all three mutant Mef-ps-IKs complexes was observed compared to WT Mef-ps-IKs (Figure 4A, Table 3), and the small but statistically significant change in free energy observed for the Y46C mutant complex indicates that Y46 residue is not as important as K41 and W323 for mefenamic acid binding. Furthermore, the flexibility of the external ps-KCNE1 protein residues of the mutants W323A and K41C ps-IKs channels was analyzed by monitoring their average root mean square fluctuation (RMSF) during the last 100 ns of simulations after the detachment of mefenamic acid from the molecular complex. The RMSF values obtained from the two mutant channels were then compared to that of WT ps-IKs channels where MD simulations of the same duration were conducted after removing the mefenamic acid molecule from the complex (Figure 4B). The results indicate that W323A and K41C mutations markedly increased the RMSF of D39-A44 ps-KCNE1 residues when compared to the WT ps-IKs channel complex without mefenamic acid bound (Figure 4C, 4D). These results suggest that the side chains of K41 and W323 residues normally stabilize the conformation of the external region of KCNE1, so that mutation of these residues increases random motion and reduces the ability of drugs like mefenamic acid to remain bound at this site.
Mutational impact on IKs current changes induced by DIDS
To establish whether the binding pocket for mefenamic acid can be generalized to other IKs activators, we also examined the binding of the structurally unrelated IKs activator, DIDS. Stilbenes such as DIDS (Figure 5A) also activate IKs (Abitbol et al., 1999Bollmann et al., 2020), and given their molecular differences from fenamates, it is of interest to explore common structural and dynamic features of their binding to the IKs channel complex. 100 µM DIDS had no effect on endogenous currents in GFP-transfected tsA201 cells but treatment of WT EQ channels with 100 µM DIDS transformed the slowly activating waveform into one with faster onset (although not instantaneous like mefenamic acid) and inhibited tail current decay (Figure 5B). G-V plots were obtained from the tail amplitudes in the absence and presence of 100 µM DIDS (Figure 5C, 5D). The overall shape, slope, and V1/2 of the WT EQ G-V relationship changed with 100 µM DIDS in the direction of increased activation (ΔV1/2 = -46.6 mV; Table 4; control k = 20.3 mV, DIDS k = mV). However, the effects on WT EQ were less pronounced with DIDS than mefenamic acid at the 100 µM concentration.
The ps-IKs construct and docking procedures used previously to explore the binding site of mefenamic acid were used as a basis for DIDS docking and subsequent MD simulations. We found that DIDS also bound to a location formed between extracellular KCNE1 residues, the external S6 transmembrane helix of one subunit, the S1 transmembrane domain of the neighboring subunit, and the pore turret of the opposite subunit (Figure 6A). DIDS is stabilized by its hydrophobic and van der Waals contacts with KCNQ1 and KCNE1 subunits as well as by two hydrogen bonds formed between the drug and ps-KCNE1 residue L42 and KCNQ1 residue Q147. The energy decomposition per amino acid using MM/GBSA and MM/PBSA methods revealed several residues in KCNQ1 and psKCNE1 with significant contributions to DIDS coordination (Figure 6B). Although residues identified as critical to mefenamic acid binding and action also generally appear to be important for DIDS, especially W323, K41 was noticeably not as critical to DIDS coordination whereas A44 and Y46 were more so.
Similar to mefenamic acid, DIDS stayed bound to WT ps-IKs, but detached from the W323A mutant during two of three runs, and from Y46C channels in one of three runs after 240 and 122 ns of simulation, respectively (Supplemental movies S5, S7). Interestingly, DIDS did not unbind from K41C mutant ps-IKs channels, even after 250 ns of simulation, although the binding pose did change in one run (Supplemental movie S6). Calculations of free interaction energy shown in Table 5 using both PBSA and GBSA methods are of mean values before the detachment of the drug if that occurred. If DIDS detachment did not occur during 250 ns MD runs, average free energy was calculated over the duration of the entire MD run for that construct. Only DIDS binding to W323A, and to Y46C in one simulation run, showed significantly lower free energy than DIDS binding to WT, using both methodologies. The small change in free energy and more stable binding of DIDS to K41C suggest that this residue is not as important as W323 or Y46 for DIDS binding.
These model predictions were tested experimentally using fully saturated mutant IKs channel complexes, K41C-EQ, L42C-EQ, A44C-EQ, Y46A-EQ, EQ-W323A, EQ-L142C and EQ-Y148C (e.g. Figure 7A). Y46 was identified as an important residue for DIDS binding in MD simulations, but as before, the complexity of the GV curve and low functional expression of the Y46C construct led us to substitute Y46A for this mutation in electrophysiology experiments (Figure 7 and Figure 7-figure supplement 1).
K41C-EQ G-V plots were obtained from peak tail current amplitudes in the absence and presence (Figure 7B) of 100 µM DIDS. Unlike with mefenamic acid, but in agreement with the modeling, K41C did not prevent the action of DIDS. Treatment of K41C-EQ with 100 µM DIDS hyperpolarized the V1/2 and changed the shape of the G-V relationship compared to control (Figure 7B, 7D, Table 4). The current waveform of K41C-EQ activated more quickly with less sigmoidicity after treatment with DIDS, and tail current decay was slowed as indicated by the normalized response (Figure 7B, 7C). As K41C-EQ remained responsive to DIDS, and L42C responded similarly to K41C-EQ (for K41C-EQ, ΔV1/2 was -24.7 mV, and for L42C-EQ ΔV1/2 was -34 mV), we hypothesized that DIDS binding to IKs channel complexes involved KCNE1 residues closer to the transmembrane region as predicted by the ligand interaction map for DIDS (Figure 6A). In agreement with this idea, A44C showed little response to 100 µM DIDS both in term of current waveform and tail current decay. The shift in V1/2 was also reduced compared to WT-EQ (A44C-EQ ΔV1/2 = -18.5 mV; WT EQ ΔV1/2 = -46.6mV, Figure 7C, D). In Y46A, the effect of DIDS on the current waveform was greatly reduced as was slowing of tail current decay (Figure 7A, 7C). We could only estimate an activation V1/2 for Y46A as the G-V curve was right shifted to very positive potentials and non-saturating. Nevertheless, hyperpolarization of the V1/2 (Figure 7D, Figure 7-figure supplement 1) in the presence of DIDS was observed, suggesting that unstable and short-lived binding of the drug to the channel complex was sufficient to interfere with channel gating.
The modeling studies (Figure 6) suggested that W323 remained a key residue for IKs activator sensitivity, and in agreement with this, EQ-W323A was only partially responsive to DIDS. In EQ-W323A, the tail current decay was affected but the slowly-activating current waveform was preserved in the presence of DIDS, supporting the idea that the drug dissociates from the channel complex between pulses (Figure 7A, 7C, Table 5). However, a significant shift in the V1/2 remained (ΔV1/2 = -27.3 mV; Figure 7D, Table 4). Comparable effects observed in EQ-W323A, A44C-EQ, and Y46A-EQ are consistent with the idea that the DIDS binding pocket involves the N-terminal end of S6 and the deeper extracellular surface of the KCNE1 transmembrane segment. In EQ-Y148C, the V1/2 and the shape of the G-V plot were not altered by 100 µM DIDS (Figure 7D, Table 4), and tail current decay was not markedly slowed (Figure 7A, 7C). This result suggests that unlike mefenamic acid, DIDS binding determinants extend to the S1 region of KCNQ1 and that Y148 is an important contributor.
Notably, as with mefenamic acid, the L142C-EQ G-V plot became voltage-independent after treatment with 100 µM DIDS (data not shown) and so it proved hyper-responsive to both of the IKs activators, DIDS and mefenamic acid.
Mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and the structurally distinct stilbenes DIDS and SITS, among other compounds, have previously been identified by numerous groups to enhance IKs currents in various expression systems including canine and guinea-pig ventricular myocytes (Magyar et al., 2006Toyoda et al., 2006) as well as heterologous expression systems such as Xenopus laevis oocytes, CHO, COS-7, tsA201 and LM cells (Busch et al., 1994Abitbol et al., 1999Unsöld et al., 2000Toyoda et al., 2006Wang et al., 2020). The extracellular region of KCNE1 between residues 39-44 was found important in mediating the effect of DIDS on IKs (Abitbol et al., 1999) and residue K41, located on the extracellular end of KCNE1, was found to be critical in mediating mefenamic acid’s activating effect on the fully saturated IKs channel complex (Wang et al., 2020). Consistent with this idea, when all four WT KCNE1 subunits are replaced with mutant K41C-KCNE1, mefenamic acid up to a concentration of 1 mM is largely ineffective (Figure 1). Unlike in the WT complex, there is little change to the current waveform, slope or V1/2 of the G-V plot during activator exposure, suggesting that all the drug binding site(s) on the channel complex are impaired, or that the mechanism of action is disabled, or that the mutation causes a combination of these actions. In the present study, we analysed these activator compound actions using molecular modeling approaches, and complementary mutational analysis. Our data describe the formation of a drug binding pocket between the immediate extracellular residues of KCNE1, S1 and pore residues of two KCNQ1 subunits, stabilized by the presence of structurally different activator compounds. The effect of mutations that negate the activator compound actions is to destabilize the binding pocket itself, reduce drug binding and limit activator residency time on the channel complex.
Mefenamic acid binding site in IKs
Using data that suggested an extracellular binding site for mefenamic acid was at the KCNE1-channel interface, MD simulations were used to explore drug-channel interactions further. The drug binding pocket was defined as the extracellular space formed by KCNE1, the domain-swapped S1 helices of one KCNQ1 subunit and the pore/turret region made up of two other KCNQ1 subunits (Figure 2; Supplemental movie S1). Docking and molecular simulations identified a binding site made up of several residues across all of these elements (Figure 2 and Figure 2-figure supplement 2, Table 6). Mutagenesis revealed that most mutations impacted at least one out of the three mefenamic acid effects: V1/2 shift, GV-plot slope change, and current waveform change related to slowed deactivation. However, only three of the mutants impacted all of the mefenamic acid actions (Figure 3). These were W323A in KCNQ1, as well as K41C, and A44C in KCNE1, which define key components of the binding pocket for mefenamic acid. That W323 forms an important medial wall of the hydrophobic pocket to which mefenamic acid binds is suggested by data from mutants in which the size of the side chain at this location is systematically made smaller to cysteine then alanine, which results in diminished effectiveness of the drug, particularly with alanine. This mutation resulted in the detachment of mefenamic acid as well as lower interaction energy of drug-channel complexes during MD simulations (Figure 4A; Supplemental movie S3) particularly loss of interaction strength with KCNE1 (Table 6). Likewise, MD simulations revealed detachment of mefenamic acid and reduced interaction energy values for K41C-Mef-Iks complexes (Supplemental movie S2, Figure 4A) again accompanied by loss of interaction strength with KCNE1 (Table 6). The drug also detached from the A44C complex, another mutant with a reduced response in terms of changes in waveform, V1/2 and slope. In contrast, while the free interaction energy of the mutant Y46C channel was significantly decreased in comparison to the WT channel complex (Figure 4A), detachment of mefenamic acid from the mutant channel during 300 ns MD simulations was not observed, though S1 appears to pull away from the pore (Supplemental movie S4). Comparison of energies at specific residues show a loss of interaction with Q147 and Y148 in S1 with this mutant and a small shift towards the turret at S298 and A300 (Figure 8A; Table 6). While we were not able to obtain good electrophysiological data from Y46C, data from Y46A suggested that mefenamic acid still had potent actions on this mutant. The combination of binding studies and electrophysiological data indicate that Y46 was not as important for mefenamic acid binding and action as other KCNE1 N-terminal residues.
Common binding site for IKs activators, mefenamic acid and DIDS
Although it was suggested that DIDS and mefenamic acid have the same binding site (Abitbol et al., 1999), the extent of overlap was unknown. Initially, we examined the effect of DIDS on WT EQ. Consistent with previous studies (Abitbol et al., 1999Bollmann et al., 2020) we confirmed that 100 µM DIDS enhanced WT EQ activity (Figure 5B) with a V1/2 shift of -46.6 mV and a decrease in the slope of the G-V curve (Table 4). As most IKs activators are dependent on the KCNQ1-KCNE1 stoichiometry, this more potent effect of DIDS seen in our study may be explained by the higher dose we used and our KCNE1-KCNQ1 linked channel constructs, which ensured fully KCNE1-saturated complexes. Furthermore, due to the large size and complex folds found on the surface of oocytes, higher drug concentrations than those used for cultured cells are often required in order to facilitate a similar effect in both expression systems (Kvist et al., 2011). All previous studies utilized Xenopus laevis oocytes, whereas in this study transiently transfected tsA201 cells were used.
In silico DIDS docking revealed that both mefenamic acid and DIDS bind to the same general extracellular inter-subunit interface with some differences in key residues revealed by the electrophysiology data. Mutation Y148 in KCNQ1 to a cysteine (Y148C) or Y46 in KCNE1 to an alanine (Y46A) was found to reduce effects of 100 µM DIDS, particularly in the case of Y148C (Figure 7). These data suggest that DIDS resides deeper in the binding pocket formed by KCNE1 residues and the KCNQ1 pore/S6, and so was less dependent on the side chain of K41 to retain the activator on the channel complex (compare Movies S1 and S6). DIDS associated more strongly with the pore of the Y148C mutant, particularly with V324 and T327, and less across the KCNE1/3, S1 and turret regions (Table 6). The Y46C mutation resulted in shifts away from KCNE1/3 and towards the S1 domain (T144, E146 and Q147). In the case of A44C and DIDS, the changes were more subtle, with stronger interactions moving from central residues in KCNE1 (K41, L42 and E43) and S1 (V141 and L142; coloured grey in Figure 8B) to more peripheral residues (I145, E146 and Q147) and lower in the KCNE TMD (A44 and M45; coloured magenta in Figure 8B).
Proposed mechanism of action for mefenamic acid and DIDS
Molecular modeling and docking revealed that mefenamic acid and DIDS induce conformational changes in the channel upon binding, to shape a binding pocket formed by residues from the external S1 domain, KCNE1 and the pore domain of IKs (Figure 2C, Supplemental movies S1, S5). This cryptic binding pocket is not detectable in the absence of the drug (Figure 4B), which suggests that it has been induced in a similar manner to previous reports of toxin interactions with KcsA-Kv1.3 that induce conformational changes in both the toxin and the channel structure to generate a high-affinity binding site (Lange et al., 2006Zachariae et al., 2008). Given the high modeled binding energy of the channel-drug activated state complexes, ~-39 kcal/mol for mefenamic acid and ~-35 kcal/mol for DIDS, but the relatively low affinities, given the micromolar concentrations required experimentally, we can imagine a dynamic complex where mefenamic acid and DIDS bind/unbind from IKs at high frequency. Slowed deactivation may therefore be the result of these rapid binding/unbinding interactions slowing the dissociation of the S1/KCNE1/pore domain/drug complex by either providing steric hindrance to dissociation or by stabilizing the activated complex. MD simulations suggest the latter is most likely the case. Our data indicate that mutation of residue W323 to an alanine would not only destabilize the external S1/KCNE1/pore domain interface (Figure 4D, Table 1) but also eliminate direct hydrophobic contacts which normally occur between the W323 side chain and mefenamic acid, thus facilitating drug dissociation (Figure 2D, Supplemental movie S3).
A reduced interaction with S1 could also conceivably curtail the ability of IKs activators to slow dissociation of the activated complex and restore faster deactivation rates such that there is no longer an enhanced step current in the presence of the drug, as seen in mutants K41C and A44C for mefenamic acid (Figure 1A and 3A) and A44C, Y46A, W323A and Y148C for DIDS (Figure 7A). Similarly, electrostatic interactions of residue K41, which acts as a lid for the binding pocket for mefenamic acid (Supplemental movie S2), could help stabilize the protein-protein interface at the external region of the channel complex. Mutation of residue K41 to a cysteine may prevent stable IKs activator binding to the channel by increasing the fluctuations of the external KCNE1 region (Figure 4C) and by reducing van der Waals contacts with the drug (Figure 2D). In simulations, mefenamic acid was seen dissociating from mutant K41C, A44C, and W323A channel complexes, and this explains why the electrophysiological effects of IKs activators were prevented by the mutational substitutions at these locations (Supplemental movies S2, S3). Shifts in, and particularly reductions in KCNE1/3 association for both drugs (Table 6) that lead to loss of efficacy suggest that it is the interactions with KCNE1 and S1 that are key to maintaining the activated state. This is similar to the proposal for tight interactions between S1 and KCNE3 in maintaining constitutive activity in KCNE3-associated channels (Kasuya and Nakajo, 2022).
In close proximity to this drug-binding pocket are known gain-of function mutations in S1, S140G and V141M, which have previously been reported to slow deactivation in the presence of KCNE1 (El Harchi et al., 2010Peng et al., 2017). As their current waveforms are qualitatively similar to those seen after exposure of WT EQ to IKs activators, we propose that the same mechanism may underlie the effects of mefenamic acid, DIDS and these IKs S1 mutations. In addition, we find that mutation of the neighboring residue, L142, also produces current waveforms and G-V plots which mirror those seen when WT EQ is treated with 100 µM mefenamic acid (Figure 3-figure supplement 1) or DIDS. In the cryo-EM structure of KCNQ1-KCNE3 (Sun and MacKinnon, 2020), residue L142 interacts with KCNE3, whereas V141 interacts with both KCNE3 and the pore domain. This suggests that both the V141M and L142C mutations could directly alter the interaction of the S1 domain with the pore and/or the position or movement of KCNE1. The co-evolved interface between the extracellular end of S1 and the pore domain is thought to be important for bracing the VSD, to allow efficient force transmission to the pore (Lee et al., 2009), but can also impact permeation, as the S140G and V141M mutations also enhance rubidium permeation through IKs complexes (Peng et al., 2017). The importance of this S1-pore coupling to channel function is supported by mutational analyses of S1 residues (Chen et al., 2003Hong et al., 2005Wang et al., 2011Campbell et al., 2013) as well as the L142C mutation examined in this study (Figure 3-figure supplement 1), which all display current waveforms with instantaneous onset. Incidentally, A300, a residue in the pore region of KCNQ1, which also interacts with both mefenamic acid and DIDS in MD simulations (Figure 2-figure supplement 2, Figure 6), has also been implicated in the same gain-of-function cleft as S140G and V141M (Smith et al., 2007). The V300T mutant has an ~-20 mV shift in V1/2 of activation and faster rates of activation (Bianchi et al., 2000), once again showing how a mutation can mirror the effects of the two activators studied here.
Binding of mefenamic acid and DIDS to the extracellular end of KCNE1 and the KCNQ1 S6 and S1 helices is facilitated by a number of key residues. Residue K41 acts as a “lid” holding mefenamic acid in place, while residue W323 impacts the size of the binding pocket. Size reduction mutations of either residue destabilize mefenamic acid binding and ultimately lead to drug detachment from the channel complex. This explains why, when all four IKs subunits are mutated, as in the case of K41C-EQ, EQ-W323A and A44C-EQ, little to no effect of the drug is seen. The larger drug, DIDS, interacts with many of the same residues but those deeper in the pocket appear more important than for mefenamic acid. Furthermore, the qualitative similarities between the S1 mutant channel, EQ-L142C and WT EQ in the presence of 100 µM mefenamic acid suggest that IKs activators most likely cause their effects by modulating interactions between the S1 helix, pore turret, KCNE1 and the S6 helix. Upon binding, both DIDS and mefenamic acid induce conformational changes in an occult binding pocket and stabilize the S1/KCNE1/pore complex, which ultimately slows deactivation. The results indicate that this extracellular inter-subunit interface forms a generalized binding site which different drugs can access and through which induce common effects on channel activation and deactivation. The presence of such a binding site and the variable nature of IKs complex composition may serve as starting points for future drug development projects targeted at discovering therapeutically-useful IKs agonists.
Materials and Methods
Drug docking and Molecular Dynamic simulations
A model of the IKs channel complex – termed pseudo-KCNE1-KCNQ1 (ps-IKs) – was created based on the cryogenic electron microscopy (cryo-EM) structure of KCNQ1-KCNE3 (PDB ID: 6v01) (Sun and MacKinnon, 2020). In this structure, the extracellular residues of KCNE3, R53-Y58, were substituted with homologous KCNE1 residues D39-A44. Conformational sampling was then performed for substituted residues and the lowest free energy conformations were selected for subsequent docking experiments applying a four-dimensional (4D) docking approach which accounts for the flexibility of the receptor site configuration (Bottegoni et al., 2009). A receptor ensemble was then created via another round of conformational sampling for the external part of ps-KCNE1 and its KCNQ1 neighborhood (8 Å cut-off distance) and generated conformations were used for a new docking iteration. A ligand-channel conformation with the lowest free energy was chosen from final docking iterations. The docking and conformational sampling experiments as well as in silico mutations described in this study were performed with ICM-pro 3.8 software (Molsoft LLC, San Diego) (Neves et al., 2012). The coordinates of selected mefenamic acid-bound ps-IKs channel complexes with the lowest free energy were then used for MD. To keep the voltage-sensing domain (VSD) in its upstate conformation, we restrained the PIP2 molecule in its crystallographic position during MD simulations. Simulations were performed in a water environment with AMBER20 using a ff14SB force field for proteins and GAFF/AM1-BCC scheme for the ligand parameterization and calculation of the atomic point charges (Jakalian et al., 2002Case et al., 2005Maier et al., 2015). The complex was solvated with TIP3P water models and Na+/Cl- at 100 mM concentration. The system was minimized and equilibrated during 10 ns. In all simulations described in this study the Langevin thermostat was set with collision frequency 2 ps-1, the reference temperature 310 degrees K, and Monte Carlo barostat with reference pressure at 1 bar (Oliver et al., 1997Wu et al., 2016). The long-range electrostatic interactions with a cut-off at 10 Å were treated with the Particle Mesh Ewald (PME) method. Bonds involving only hydrogens were constrained with the SHAKE algorithm and a 2 fs integration time step was used. The 2D diagrams in Figures 2 and 6 were generated by ICM pro software. Cut-off values are as follows: hydrophobic contacts 4.5 Å and hydrogen bond strength 0.8. Hydrogen bond strength is a unitless parameter for H-bond calculation in ICM-pro and lower values identify weaker hydrogen bonds. The values do not represent H-bond energy. The MM/PBSA and MM/GBSA methods were used to calculate the free energy of binding as described previously (Miller et al., 2012) after collection of 1000 snapshots for each run. A schematic representation of the general workflow for ps-IKs model construction, drug docking and MD simulations can be found in Figure 2-figure supplement 1.
Reagents and solutions
DIDS (Sigma-Aldrich, Mississauga, ON, Canada) was prepared as a 50 mM stock solution dissolved in 100% dimethyl sulfoxide. Stock DIDS solution was diluted in control whole-cell bath solution to obtain a final DIDS concentration of 100 µM which was perfused onto mammalian cells for whole-cell experiments. All other reagents and solutions were prepared as described (Wang et al., 2020). Mefenamic acid (Tocris Bioscience, Oakville, ON, Canada) was used at concentrations of 100 μM and 1 mM. To block IKs, the specific IKs inhibitor HMR1556 (Tocris Bioscience, Oakville, ON, Canada) was used at a concentration of 0.3-1 µM.
Molecular biology, cell culture and whole cell patch clamp
tsA201 transformed human embryonic kidney 293 cells were first cultured, then plated for whole-cell experiments and, finally, transfected with Lipofectamine2000 (Murray et al., 2016Westhoff et al., 2019Wang et al., 2020). All mutations were first generated using site-directed mutagenesis and Pfu turbo, then sequence confirmed. Whole-cell experiments were conducted 24-48 h post transfection. For wildtype (WT) EQ and mutant x-EQ-Y (where “x” denotes a KCNE1 mutation and “y” denotes a KCNQ1 mutation; for example, K41C-EQ, EQ-W323A), cells were transfected with a linked KCNE1 and KCNQ1 cDNA (2-3 µg was used) which assembles as a fully saturated 4:4 ratio of KCNE1 to KCNQ1. All constructs were also co-transfected with 0.8 µg of GFP to allow transfected cells to be identified. Data were obtained using an Axopatch 200B amplifier, Digidata 1440A digitizer and pCLAMP 11 software (Molecular Devices, LLC, San Jose, CA).
Conductance-voltage (G-V) relationships were obtained from the normalized peak of the initial tail current (G/Gmax) and plotted against the corresponding voltage. G-V plots were fitted with a Boltzmann sigmoid equation to obtain the voltage at half-maximal activation (V1/2) and slope (k) values (Tables 1 to 3). For each EQ mutant, the change in activation V1/2 (ΔV1/2=V1/2 in the presence of drug-V1/2 control) was also determined (Figures 3E and 7E). In some cases, the foot of the G-V curve did not reach 0 (essentially in the presence of drug) and as a result, the V1/2 was read directly from the plots. Slowing of tail current decay was used as a measure of mefenamic acid and DIDS impact on WT and mutated EQ channel complexes. Specifically, the peak to end difference currents were calculated by subtracting the minimum amplitude of the deactivating current from the peak amplitude of the deactivating current. The difference current in mefenamic acid or DIDS was normalized to the maximum control (in the absence of drug) difference current and subtracted from 1.0 to obtain the normalized response (Figures 3D and 7C).
GraphPad Prism 9 (GraphPad Software, San Diego, CA) was used to analyze all the data. Where applicable, unpaired t-test or one-way ANOVA followed by the Fisher’s least significant difference (LSD) test was used to determine statistical significance. In all figures ****, ***, **, * denotes a significance where p<0.0001, p<0.001, p<0.01 and p<0.05, respectively. All data in the figures and tables are shown as mean ± SD or SEM. Bar graphs showing mean ΔV1/2 (Figures 3E and 7D) were generated by calculating changes in V1/2 induced by drug treatment vs. control in separate cells. ΔV1/2 values reported in the Results were calculated from the mean V1/2 values shown in Tables 1 and 3.
delayed cardiac rectifier K+ current
long QT syndrome
voltage at half-maximal activation
Poisson-Boltzmann surface area
generalized Born surface area.
We thank Fariba Ataei for her assistance in cell culture and for making mutants.
Participated in research design
Jodene Eldstrom, David Fedida, Vitya Vardanian, Harutyun Sahakyan, Magnus Chan, Marc Pourrier, Yundi Wang
Magnus Chan, Harutyun Sahakyan, Daniel Sastre, Marc Pourrier, Jodene Eldstrom, Yundi Wang, Ying Dou, David Fedida
Performed data analysis
Magnus Chan, Jodene Eldstrom, Harutyun Sahakyan, Yundi Wang
Wrote or contributed to the writing of the manuscript
David Fedida, Harutyun Sahakyan, Jodene Eldstrom, Magnus Chan, Marc Pourrier, Yundi Wang, Vitya Vardanian
This research was funded by Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2016-05422), Canadian Institutes of Health Research (#PJT-156181) and Heart and Stroke Foundation of Canada (#G17-0018392) grants to D.F. and grants from the Volkswagen Foundation (#AZ86659 and AZ 92111) to V.V.. MC holds an NSERC CGS-M scholarship. Y.W. holds a CIHR– Vanier CGS scholarship.
- Stilbenes and fenamates rescue the loss of I KS channel function induced by an LQT5 mutation and other IsK mutantsEMBO Journal 18:4137–4148
- HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)Europace 13:1077–1109
- K v LQT1 and IsK (minK) proteins associate to form the I Ks cardiac potassium currentNature 384:78–80
- In vitro molecular interactions and distribution of KCNE family with KCNQ1 in the human heartCardiovascular Research 67:529–538
- Mechanisms of I Ks suppression in LQT1 mutantsAmerican Journal of Physiology: Heart and Circulatory Physiology 279
- 4,4’-Diisothiocyanato-2,2’-Stilbenedisulfonic Acid (DIDS) Modulates the Activity of KCNQ1/KCNE1 Channels by an Interaction with the Central Pore RegionCell Physiol Biochem 54:321–332
- Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand dockingJournal of medicinal chemistry 52:397–406
- Positive regulation by chloride channel blockers of I sK channels expressed in Xenopus oocytesMol.Pharmacol 46:750–753
- Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillationCirc Arrhythm Electrophysiol 6:960–966
- The Amber biomolecular simulation programsJournal of computational chemistry 26:1668–1688
- KCNQ1 gain-of-function mutation in familial atrial fibrillationScience 299:251–254
- Location of KCNE1 relative to KCNQ1 in the I(KS) potassium channel by disulfide cross-linking of substituted cysteinesProc.Natl.Acad.Sci.U.S.A 106:743–748
- The S140G KCNQ1 atrial fibrillation mutation affects ‘I(KS)’ profile during both atrial and ventricular action potentialsJ Physiol Pharmacol 61:759–764
- The voltage-gated channel accessory protein KCNE2: multiple ion channel partners, multiple ways to long QT syndromeExpert.Rev.Mol.Med 13
- ML277 regulates KCNQ1 single-channel amplitudes and kinetics, modified by voltage sensor stateJ Gen Physiol 153
- How does KCNE1 regulate the Kv7.1 potassium channel? Model-structure, mutations, and dynamics of the Kv7.1-KCNE1 complexStructure 20:1343–1352
- The Genetic Basis of Long QT and Short QT Syndromes: A Mutation UpdateHuman Mutation 30:1486–1511
- De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in uteroCardiovascular Research 68:433–440
- Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validationJournal of computational chemistry 23:1623–1641
- Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden deathAm Heart J 54:59–68
- Optimized tight binding between the S1 segment and KCNE3 is required for the constitutively open nature of the KCNQ1-KCNE3 channel complexElife 11
- Allosteric mechanism for KCNE1 modulation of KCNQ1 potassium channel activationElife 9
- The use of Xenopus oocytes in drug screeningExpert Opin Drug Discov 6:141–153
- Toxin-induced conformational changes in a potassium channel revealed by solid-state NMRNature 440:959–962
- Two separate interfaces between the voltage sensor and pore are required for the function of voltage-dependent K(+) channelsPLoS.Biol 7
- L-364,373 fails to activate the slow delayed rectifier K+ current in canine ventricular cardiomyocytesNaunyn Schmiedebergs Arch Pharmacol 373:85–89
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SBJournal of chemical theory and computation 11:3696–3713
- Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activatorBioorg Med Chem Lett 22:5936–5941
- MMPBSA.py: An Efficient Program for End-State Free Energy CalculationsJournal of chemical theory and computation 8:3314–3321
- Discovery of a novel activator of KCNQ1-KCNE1 K channel complexesPLoS One 4
- Unnatural amino acid photo-crosslinking of the channel complex demonstrates a KCNE1:KCNQ1 stoichiometry of up to 4:4Elife 5
- Docking and scoring with ICM: the benchmarking results and strategies for improvementJournal of computer-aided molecular design 26:675–686
- Atrial fibrillation: the role of common and rare genetic variantsEur J Hum Genet 22:297–306
- Markov chain Monte Carlo methods for conditioning a permeability field to pressure dataMathematical Geology 29:61–91
- Gating mechanisms underlying deactivation slowing by two KCNQ1 atrial fibrillation mutationsSci Rep 7:45911
- Coassembly of K v LQT1 and minK (IsK) proteins to form cardiac I Ks potassium channelNature 384:80–83
- Structural models for the KCNQ1 voltage-gated potassium channelBiochemistry 46:14141–14152
- Structural Basis of Human KCNQ1 Modulation and GatingCell 180:340–347
- Modulation of functional properties of KCNQ1 channel by association of KCNE1 and KCNE2Biochemical and Biophysical Research Communications 344:814–820
- KCNE1 reverses the response of the human K + channel KCNQ1 to cytosolic pH changes and alters its pharmacology and sensitivity to temperaturePflugers Archiv European Journal of Physiology 441:368–378
- Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmiasNat.Genet 12:17–23
- The I Ks Ion Channel Activator Mefenamic Acid Requires KCNE1 and Modulates Channel Gating in a Subunit-Dependent MannerMol Pharmacol 97:132–144
- Probing the structural basis for differential KCNQ1 modulation by KCNE1 and KCNE2J.Gen.Physiol 140:653–669
- Gating-related molecular motions in the extracellular domain of the IKs channel: implications for IKs channelopathyJ Membr Biol 239:137–156
- I Ks ion-channel pore conductance can result from individual voltage sensor movementsProc Natl Acad Sci U S A 116:7879–7888
- Structural and electrophysiological basis for the modulation of KCNQ1 channel currents by ML277Nature Communications 13
- Self-guided Langevin dynamics via generalized Langevin equationJournal of computational chemistry 37:595–601
- KCNQ1 and KCNE1 in the IKs channel complex make state-dependent contacts in their extracellular domainsJ.Gen.Physiol 131:589–603
- Probing binding sites and mechanisms of action of an I(Ks) activator by computations and experimentsBiophys J 108:62–75
- Dynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channelsProc.Natl.Acad.Sci.U.S.A 110:8732–8737
- The molecular mechanism of toxin-induced conformational changes in a potassium channel: relation to C-type inactivationStructure 16:747–754
- Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator which rescues LQTs mutantsPLoS One 7